Jiahui Li and Shannuo Li were selected by the organizers of the AAPS Annual meeting (Salt Lake City, October 20-23,2024) for oral Rapid-Fire Presentations.
Jiahui Li’s submission, “Combination of Chemo-immunotherapy with N-(2-Hydroxypropyl) methacrylamide-based Polymer Conjugates for Cancer Treatment,” highlights the development and efficacy of a second-generation, long-circulating HPMA copolymer-epirubicin conjugate (KT-1) and its combination with an HPMA-based multivalent polymer-peptide anti-PD-L1 antagonist (MPPA) in treating cold tumors. By effectively inducing immunogenic cell death and redirecting PD-L1 to lysosomal degradation, this dual approach has shown significant improvements in responsiveness and treatment outcomes in both the 4T-1 murine triple-negative breast cancer model and B16F10 melanoma-bearing C57BL/6 mice, offering a promising pathway for future therapeutic strategies.
Shannuo Li’s presentation,”Multi-Antigen T Cell Hybridizers for Personalized Treatment of MM,” focuses on a novel and versatile approach to enhance the precision and efficacy of T cell-based immunotherapy for multiple myeloma. The study aims to assess the effectiveness of MATCH in enhancing T cell-mediated responses against multiple myeloma cells and the mechanisms involved. MATCH functions by efficiently recruiting and activating T cells via Fab’CD3-MORF2, leading to the release of cytotoxic granules and cytokines and initiating Fas-FasL binding. This orchestrated release of “bio-bullets” is intended to drive additive cytotoxicity, resulting in the targeted death of cancer cells through both apoptosis and necroptosis
